ライフサイエンスコーパス: immunocompetent

1 virus, even in patients who were previously immunocompetent.

2 r vaccine to indicated adults while they are immunocompetent.

3 In particular, we find that in immunocompetent adolescents with cervical HPV infections

4 rbaspirillum aquaticum or H. huttiense in an immunocompetent adult male.

5 We found that immunocompetent adult mice and hamsters did not become i

6 V-GPC was unable to establish persistence in immunocompetent adult mice, which prevented its use for

7 Participants were immunocompetent adult patients (age range, 18-64 years)

8 t of antifungal prevention in critically ill immunocompetent adult patients on mortality and subseque

9 do not, without adaptation, cause disease in immunocompetent adult rodents.

10 (VZV) contained in Zostavax in a 68-year-old immunocompetent adult with strong evidence of prior wild

11 In immunocompetent adults >/=65 years of age, PCV13 elicits

12 st because of its ability to persist in most immunocompetent adults and because of the lack of a prot

13 Immunocompetent adults are rarely affected.

14 s, together with gene expression profiles in immunocompetent adults experiencing a severe primary HCM

15 ria of >10 nucleated cells/mul in the CSF of immunocompetent adults for viral CSF NAAT assays would i

16 Emory University that enrolled non-pregnant, immunocompetent adults from Atlanta, GA, USA, who were a

17 A total of 115 cytomegalovirus seropositive, immunocompetent adults with critical illness were enroll

18 Immunocompetent adults with histologically confirmed PCN

19 e to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma.

20 ized specific immunity in 207 nonsymptomatic immunocompetent and 132 immunocompromised individuals in

21 chopulmonary aspergillosis (ABPA) in overtly immunocompetent and atopic individuals, respectively.

22 The dominant mechanism of TA-GVHD in both immunocompetent and compromised hosts is exposure to via

23 ectrum of infection-related diseases in both immunocompetent and immunocompromised hosts, ranging fro

24 proteins, which had therapeutic efficacy in immunocompetent and immunocompromised mice.

25 dy, we examined mucosal infection in several immunocompetent and immunocompromised mouse strains.

26 atures of pulmonary nocardiosis and compared immunocompetent and immunocompromised patients.

27 suggest that M. amphoriforme may infect both immunocompetent and immunocompromised people.

28 bpA/B-deficient spirochetes occurred in both immunocompetent and immunodeficient mice in a manner ind

29 acy, mechanisms and safety of TSO therapy in immunocompetent and immunosuppressed animals.

30 titration studies evaluating these islets in immunocompetent and nonobese diabetic mouse models are u

31 gether, these data suggest that BCV protects immunocompetent and partially T cell-reconstituted immun

32 . burgdorferi to establish infection in both immunocompetent and SCID mice and has been proposed to f

33 ) of the persistently infected patients were immunocompetent, and 65% were symptomatic with relapsing

34 Geneva, Switzerland, enrolled non-pregnant, immunocompetent, and otherwise healthy adults aged 18-65

35 A robust immunocompetent animal model is still lacking, hampering

36 long-term glycemic correction of a diabetic, immunocompetent animal model using human SC-beta cells.

37 Due to a scarcity of immunocompetent animal models for viral hepatitis, littl

38 for the development of macaques and pigs as immunocompetent animal models to study HBV infection in

39 th an otherwise identical IgG in a syngeneic immunocompetent animal, and we identify TNFalpha/MCP-1 s

40 ate infection by the enteral route either in immunocompetent animals or in animals deficient in the i

41 icient animals in comparison to ticks fed on immunocompetent animals.

42 lytic activity in comparison to ticks fed on immunocompetent animals.

43 clearance of the transfected cells occurs in immunocompetent animals.

44 antibodies were detected in the sera of all immunocompetent animals.

45 icient animals in comparison to ticks fed on immunocompetent animals.

46 e where Candida albicans infections occur in immunocompetent as well as immunosuppressed individuals.

47 Similar results were obtained with immunocompetent BALB/c and C57BL/6 mice challenged i.p.

48 ept inhibited MHC-I(high) melanoma growth in immunocompetent but not in immunodeficient (IFNgamma(-/-

49 yet lost upon passage of such cells through immunocompetent (but not immunodeficient) mice.

50 to exhibit an early dissemination defect in immunocompetent, but not immunodeficient, mice, and the

51 mediated more potent antiglioma activity in immunocompetent C57BL/6 but not immunodeficient athymic

52 and IL-17 production by lung lymphocytes in immunocompetent C57BL/6 mice over time following infecti

53 ction in vitro in the presence of serum from immunocompetent C57BL/6 or immunocompromised mice lackin

54 Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mi

55 Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 x 10(4) infectious focu

56 now report that IV.3 induces anaphylaxis in immunocompetent CD32a-transgenic "FCGR2A" mice, along wi

57 Microglia, the primary immunocompetent cells in the brain, are active neonatall

58 isease characterized by many dysfunctions of immunocompetent cells.

59 alpha7 nicotinic acetylcholine receptors on immunocompetent cells.

60 Demodex folliculorum should be considered in immunocompetent children with rosacea or rosacea-like re

61 Neither the proportion of adult cases with immunocompetent comorbidities (relative risk ratio [RRR]

62 t recipients (n = 103), and 11.2 to 15.2% in immunocompetent control subjects (n = 211).

63 nse to monocrotaline challenge compared with immunocompetent controls despite daily imatinib administ

64 colon organoids we describe a broadly usable immunocompetent CRC model that recapitulates the entire

65 fungal prevention of systemic candidiasis in immunocompetent critically ill adults did not reduce mor

66 Prophylactic antiviral therapy in immunocompetent cytomegalovirus seropositive patients ad

67 h are the site of EBV persistence in healthy immunocompetent donors.

68 tocarcinogenesis in immunocompromised versus immunocompetent Fah-deficient mice.

69 32 mg/mL of methylprednisolone for 7 days in immunocompetent flies led to increased mortality and a h

70 opment of preclinical model systems that are immunocompetent for the study of human tumors.

71 orescent dye and injected intravenously into immunocompetent Friend virus B-type mice.

72 In breast carcinoma-bearing mice that were immunocompetent, GARP overexpression promoted Foxp3(+) T

73 in the CT findings of immunocompromised and immunocompetent groups.

74 SNV infection of immunocompetent hamsters results in an asymptomatic infe

75 ted]) or low risk (aged 3 years or older and immunocompetent [HIV-negative]).

76 mmune activation in DENV target organs of an immunocompetent host and supports the further developmen

77 vironment, which is quickly contained in the immunocompetent host but can cause lethal invasive asper

78 Chronic tuberculosis in an immunocompetent host is a consequence of the delicately

79 utant Braf(V600E) mouse melanoma cells in an immunocompetent host requires their production of prosta

80 ce (long-term antigen unresponsiveness in an immunocompetent host) presents the exciting prospect of

81 anding of pathogen clearance by the healthy, immunocompetent host.

82 cystis infection induces lung disease in the immunocompetent host.

83 c disease after primary CMV infection in the immunocompetent host.

84 fficiently than T3SS-positive bacteria by an immunocompetent host.

85 ivo system for the study of METDelta14 in an immunocompetent host.

86 ropism-dependent provirus elimination in the immunocompetent host.

87 perficial and cutaneous fungal infections in immunocompetent hosts and invasive disease in immunocomp

88 morbidity and sometimes fatal infections in immunocompetent hosts and is thus an important pathogen

89 norovirus cell tropism in orally inoculated, immunocompetent hosts at the peak of acute infection and

90 neously growing syngeneic prostate tumors in immunocompetent hosts improved animal survival after sur

91 ion from engineered mouse cells grafted onto immunocompetent hosts increased insulin secretion and re

92 r of T cells from DLL1-treated tumor-bearing immunocompetent hosts into tumor-bearing SCID-NOD immuno

93 latency; however, long-term EBV infection in immunocompetent hosts is limited to B cells with a more

94 eria for deferring HSV PCR testing of CSF in immunocompetent hosts with normal CSF white blood cell a

95 sa elicits strong innate immune responses in immunocompetent hosts, and the resulting recruitment of

96 esumably was developed for interactions with immunocompetent hosts, in whom organism loads are substa

97 ment and inflammatory cytokine production in immunocompetent hosts, the impact of C. gattii infection

98 immunocompromised mice, it is controlled in immunocompetent hosts, where immune cells in combination

99 us that are key for disease establishment in immunocompetent hosts-alpha-hemolysin (Hla), iron-regula

100 ckade and ADCP has yet to be demonstrated in immunocompetent hosts.

101 improved the survival of metastasis-bearing immunocompetent hosts.

102 manifests as localized cutaneous disease in immunocompetent hosts.

103 ction, which rarely progresses to disease in immunocompetent hosts.

104 he inability to mount protective immunity in immunocompetent hosts.

105 ) establishes persistent latent infection in immunocompetent hosts.

106 , which allows lifelong viral persistence in immunocompetent hosts.

107 be exacerbated by inflammatory responses in immunocompetent hosts.

108 fected neurons in both immunoincompetent and immunocompetent hosts.

109 ty of the virus to replicate specifically in immunocompetent hosts.

110 ily swabs for 20 days from each region in 28 immunocompetent, HSV-2-seropositive persons.

111 resents a successful defense mechanism by an immunocompetent human host to eliminate VZV reactivation

112 ions of VZV-infected human brain from living immunocompetent human subjects are exceedingly rare.

113 Immunocompetent humans and animals, however, can tolerat

114 hypoxia compared to the original tumours in immunocompetent humans, and hypoxia was reduced by adopt

115 IS) hosts, but an M2 predominant response in immunocompetent (IC) hosts following Pneumocystis carini

116 Hosts are considered immunocompetent if they are >/=2 years old and have not

117 signaling motifs suppresses tumor growth in immunocompetent, immunocompromised, and PD-1-deficient t

118 characterized by adjectives such as immune, immunocompetent, immunosuppressed, immunocompromised, or

119 n earlier study, we reported infection of an immunocompetent individual with multiple strains of Aero

120 , clinically apparent cancers still arise in immunocompetent individuals in part as a consequence of

121 h tropism for B lymphocytes and infection in immunocompetent individuals is typically asymptomatic an

122 Despite continuous contact with fungi, immunocompetent individuals rarely develop pro-inflammat

123 this lineage of C. gattii to be virulent in immunocompetent individuals remains unexplained.

124 B19V DNA-positive serum samples from 222 immunocompetent individuals were analyzed for (1) viral

125 tent diarrhea caused by infectious agents in immunocompetent individuals worldwide.

126 ngeal carcinomas and lymphomas developing in immunocompetent individuals, even though in these patien

127 imary infection is generally asymptomatic in immunocompetent individuals, HCMV is a significant cause

128 ng of the immune response to EBV in healthy, immunocompetent individuals, in transplant recipients, a

129 included case-control or cohort studies, in immunocompetent individuals, that calculated the odds ra

130 ive in controlling HSV-1 or -2 infections in immunocompetent individuals, their use in immunocompromi

131 cutaneous squamous cell carcinoma (cSCC) in immunocompetent individuals.

132 tions occurring in both immunosuppressed and immunocompetent individuals.

133 with other immunodeficiencies as well as in immunocompetent individuals.

134 ated nontuberculous species is increasing in immunocompetent individuals.

135 himurium causes localized gastroenteritis in immunocompetent individuals.

136 in not only immunocompromised hosts but also immunocompetent individuals.

137 uals and exacerbate chronic lung diseases in immunocompetent individuals.

138 cetate can present with vascular sequelae in immunocompetent individuals.

139 es unnoticed, causing mild or no symptoms in immunocompetent individuals.

140 sk factor for progression to tuberculosis in immunocompetent individuals.

141 ms involved during primary HCMV infection in immunocompetent individuals.IMPORTANCE HCMV-specific imm

142 Although most immunocompetent infected individuals remain asymptomatic

143 of immune control, we sought an outbred and immunocompetent laboratory mouse strain in which persist

144 n E)(-/)(-) mice) in addition to established immunocompetent LDLR(-/)(-) and ApoE(-/)(-) mice.

145 single dose protection against ZIKV using an immunocompetent lethal mouse challenge model.

146 rain is able to rapidly germinate within the immunocompetent lung environment, inducing greater lung

147 he kinetics of long-circulating liposomes in immunocompetent mammary carcinoma-bearing FVB/n and BALB

148 Observations: An immunocompetent man in his 60s presented with chronic ve

149 emphigoid animal model featuring pruritus in immunocompetent, mature, and largely unmanipulated anima

150 SKH-1 hairless and immunocompetent mice (n = 180) were fed AIN-93G or AIN-9

151 mmunophenotype an orthotopic glioma model in immunocompetent mice after Myxoma virus (MYXV) administr

152 neutrophils, CCR2(+) monocytes, or both from immunocompetent mice and determined susceptibility to in

153 of spontaneous melanoma brain metastasis in immunocompetent mice and developed molecular tools for q

154 contemporary and historical ZIKV strains in immunocompetent mice and mice lacking components of the

155 ignant gliomas were established in syngeneic immunocompetent mice and then treated with dendritic cel

156 ificantly faster clearance than unvaccinated immunocompetent mice and unvaccinated CD4-depleted mice

157 of a murine norovirus inoculated orally into immunocompetent mice are macrophages, dendritic cells, B

158 Since immunocompetent mice are resistant to infection with S.

159 of homologous B. burgdorferi to superinfect immunocompetent mice as opposed to heterologous strains.

160 d the luciferase transposon and repressor to immunocompetent mice by hydrodynamic injection, initial

161 o show that primary tumors can be modeled in immunocompetent mice by microinjecting CCR9-expressing c

162 SC)-derived hepatocyte-like cells (iPS-H) in immunocompetent mice by pre-engineering 3D cell co-aggre

163 this study was to explore the role of CG in immunocompetent mice challenged aerogenically with Mycob

164 We found that intramuscularly injected immunocompetent mice did not develop disease and that vi

165 F10 cells induced tumor growth inhibition in immunocompetent mice following a rechallenge with live c

166 These data suggest that ST-246 protects immunocompetent mice from lethality and reduces viral di

167 Specifically, vaccinated immunocompetent mice had significantly faster clearance

168 6-F10 melanoma growth in the rear footpad of immunocompetent mice induces marked B cell accumulation

169 nd adaptive responses previously observed in immunocompetent mice inoculated with trophic forms compa

170 urprisingly, after peripheral inoculation of immunocompetent mice on the day of birth, the first cell

171 that the host response to DENV infection in immunocompetent mice recapitulates transcriptional chang

172 B cell-deficient and immunocompetent mice reconstituted with T2-MZP B cells b

173 addition, CD4 T cell epitope vaccination of immunocompetent mice reduced MCMV replication in the sam

174 la enterica serovar Typhimurium infection of immunocompetent mice results in acute followed by chroni

175 Three strains of immunocompetent mice supported mucosal infections.

176 Immunocompetent mice that had been cured from NSCLC by t

177 oculation into the uterine wall of pregnant, immunocompetent mice to evaluate transplacental transmis

178 While infection of immunocompetent mice with different rVSV-based filovirus

179 describe a syngeneic orthotopic HCC model in immunocompetent mice with liver cirrhosis induced by car

180 arget for cancer immunotherapy by immunizing immunocompetent mice with Tem1 cDNA fused to the minimal

181 A single intramuscular immunization of immunocompetent mice with the MVA-ZIKV-NS1 vaccine candi

182 In immunocompetent mice, acute gammaHV68 infection results

183 n metastasis models in immunocompromised and immunocompetent mice, and tested the fate and efficacy o

184 s increased during Pneumocystis infection in immunocompetent mice, IL-17A is not required for control

185 lthough M. tuberculosis persists in lungs of immunocompetent mice, M. bovis BCG is cleared, and clear

186 ed CD45 receptor that effectively conditions immunocompetent mice.

187 s for innate allergic responses in otherwise immunocompetent mice.

188 ), can be exploited to eradicate sarcomas in immunocompetent mice.

189 prolonging recurrence-free survival only in immunocompetent mice.

190 persistent systemic inflammatory disease in immunocompetent mice.

191 er immune response upon their injection into immunocompetent mice.

192 ial tissue introduced into the peritoneum of immunocompetent mice.

193 , but limits the adaptive immune response in immunocompetent mice.

194 to levels higher than those of wild-type in immunocompetent mice.

195 ebral bodies, or inoculated in the tibiae of immunocompetent mice.

196 n inhibited growth of HCC cells in syngeneic immunocompetent mice.

197 were injected into the left flank of C57Bl6 immunocompetent mice.

198 of the lower genital tract in heterozygous (immunocompetent) mice of the NU/J strain progressed to h

199 In this study we employed an orthotopic immunocompetent model of lung adenocarcinoma in which mu

200 increase during progression in an orthotopic immunocompetent model of lung cancer.

201 In an immunocompetent model of TNBC in which Eo771/MUC1-C cell

202 erspecies transmission and establish a novel immunocompetent model system, we examined the ability of

203 logous neutralizing antibodies compared with immunocompetent monkeys.

204 Here, we establish the first genetic immunocompetent mouse model for metastatic neuroblastoma

205 In this issue of Blood, Lykken et al used an immunocompetent mouse model of B-cell lymphoma to discov

206 oft agar growth and in vivo metastasis in an immunocompetent mouse model of breast cancer.

207 Here, we show using an immunocompetent mouse model of chronic HBV infection tha

208 Using an immunocompetent mouse model of chronic HBV infection, we

209 datasets and applied expression data from an immunocompetent mouse model of metastasis as an addition

210 vitro and in vivo in a clinically relevant, immunocompetent mouse model of pancreatic ductal adenoca

211 lele induced lung adenocarcinoma in a novel, immunocompetent mouse model.

212 on of NFATc1 reduced metastasis growth in an immunocompetent mouse model.

213 I:C and CpG with trastuzumab-like therapy in immunocompetent mouse models of ErbB2(+) breast cancer.

214 In immunocompetent mouse models of HER2/ErbB2-driven breast

215 he context of anti-PD-1 therapy in two fully immunocompetent mouse models of lung adenocarcinoma.

216 ctivation is often explored using rat Abs in immunocompetent mouse models.

217 nfections in different immunocompromised and immunocompetent mouse strains.

218 Here, using syngeneic immunocompetent mouse tumor models, we reveal that the t

219 best characterized MPS-I murine model is an immunocompetent mouse, we here developed a transplantati

220 FIST15 failed to establish tumors in vivo in immunocompetent murine hosts and could only form tumors

221 cites using fluid from human patients and an immunocompetent murine model (ID8) of EOC that mirrors h

222 d CAR T-cell function following BMT using an immunocompetent murine model of minor mismatched allogen

223 ient survival, and here we demonstrate in an immunocompetent murine model that colon tumors expressin

224 ative and prophylactic treatments in healthy immunocompetent, MyD88-deficient, lymphocyte-deficient,

225 ntenance of pregnancy and the delivery of an immunocompetent neonate.

226 -4.1 cells did not prevent diabetes onset in immunocompetent NOD mice.

227 In this study, we used immunocompetent nonobese diabetic (NOD) and immunocompro

228 thobunyavirus, has only been identified in 3 immunocompetent North American patients with acute neuro

229 Reports of HHV-6A or HHV-6B encephalitis in immunocompetent older children/adults are most likely du

230 ntigen receptor construct (chNKG2D) in fully immunocompetent orthotopic glioblastoma mouse models.

231 c insights into this association in multiple immunocompetent orthotopic models of lung cancer.

232 In immunocompetent orthotopic mouse models of pancreatic ca

233 eously in living tumors and across a diverse immunocompetent patient population may provide a foundat

234 heter-associated bloodstream infection in an immunocompetent patient prior to heart transplantation.

235 vir resistant herpes simplex keratitis in an immunocompetent patient.

236 ted States, made rarer by its presence in an immunocompetent patient.

237 y to help discriminate patients with HM from immunocompetent patients (areas under the ROC curve, 0.9

238 umannii infections in a cohort of relatively immunocompetent patients (low comorbidity and illness se

239 5), but not in the 27 patient-episodes among immunocompetent patients (P = 1.0), as no neurologic seq

240 Severe Acinetobacter baumannii infections in immunocompetent patients are uncommon, and the virulence

241 Of 87461 immunocompetent patients having at least 1 claim for div

242 PAD patients in the United Kingdom and from immunocompetent patients in other countries.

243 s arising after invasive procedures, even in immunocompetent patients in seemingly sterile settings.

244 ation would affect the development of KCs in immunocompetent patients with a history of multiple KCs.

245 data suggest symptomatic treatment alone for immunocompetent patients with HSV meningitis, avoiding t

246 This cohort study included immunocompetent patients with HZ.

247 n these 28 patients with glioblastoma and 19 immunocompetent patients with PCNSL.

248 e presentation, evaluation, and treatment of immunocompetent patients with PCNSL.

249 Sixty immunocompetent patients with primary symptomatic CMV in

250 Conclusions and Relevance: In contrast to immunocompetent patients, AGWs of HIV+ MSM may harbor hi

251 ions in both immunocompromised and otherwise immunocompetent patients, although the mechanisms defini

252 and is less likely to cause fistulas than in immunocompetent patients.

253 therapy (71%) in both immunocompromised and immunocompetent patients.

254 ns, and cavity in both immunocompromised and immunocompetent patients.

255 However, it may also occur in immunocompetent patients.

256 cAbs) identical to the BCR of 23 PCNSLs from immunocompetent patients.

257 n it arises in this context compared with in immunocompetent patients.

258 tumor immunity was compromised compared with immunocompetent patients.

259 development, may be driven in part by HPV in immunocompetent patients.

260 primary HCMV infection have been reported in immunocompetent patients.

261 reak isolates in particular cause disease in immunocompetent people is unknown, with differing hypoth

262 In both immunocompromised and some immunocompetent people, EBV causes several cancers and l

263 onis is a dematiaceous fungus able to infect immunocompetent people.

264 ned susceptibility of HSV-2 to pritelivir in immunocompetent persons following daily therapy for up t

265 sex-, age-, and antibiotic treatment-matched immunocompetent persons with erythema migrans.

266 I], 8.7-15) in immunocompromised compared to immunocompetent persons; the case fatality rate was elev

267 hage-like cells in tissue and the release of immunocompetent pre-dendritic cells into the circulation

268 of hCD4/R5/cT1 mice as a highly reproducible immunocompetent preclinical model to evaluate HIV-1 acqu

269 limited capability to establish infection in immunocompetent primates due to its decreased antagonist

270 SO treatment ameliorates colitis severity in immunocompetent rabbits, modulates LPMC immune responses

271 We developed an immunocompetent rat model system of rat tumour lung meta

272 Here, an immunocompetent rat model was designed to recapitulate t

273 Herein, immunocompetent rats infected at birth with Pneumocystis

274 into adrenalectomized, immunodeficient, and immunocompetent rats.

275 ly replace the entire cervical oesophagus in immunocompetent rats.

276 er of purified Tet2-Tet3 DKO iNKT cells into immunocompetent recipient mice resulted in an uncontroll

277 s do not cause significant disease in adult, immunocompetent rodents, these models rely on "rodent-ad

278 ain function of the thymus is to generate an immunocompetent set of T cells not reactive to self.

279 We show that MmuPV1 challenge of the outbred immunocompetent SKH1 strain produces both transient and

280 In an effort to develop an immunocompetent small primate model for HCV infection to

281 A lack of immunocompetent-small-primate models has been an obstacl

282 Nine immunocompetent Sprague-Dawley rats received intravenous

283 or the meta-analysis and included 3112 adult immunocompetent study participants with cSCC and 6020 co

284 Immunocompetent subjects carrying the homozygous A haplo

285 e spray were compared with nasal washes from immunocompetent subjects during 146 upper respiratory in

286 nd without saline spray during 142 URIs from immunocompetent subjects were 96% and 86% (P = 0.004), r

287 ria of >10 nucleated cells/mul in the CSF of immunocompetent subjects would have reduced HSV-1/2, VZV

288 cells abolished radiotherapeutic response in immunocompetent syngeneic hosts.

289 of cancer-FOXP3 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromi

290 ent for negative selection and maturation of immunocompetent T cells with a self-tolerant T cell anti

291 ing in vivo and ex vivo experiments with the immunocompetent TC-1 murine tumor model, we found that m

292 four mouse models, CBA/J and C57BL6/J (both immunocompetent), Tgepsilon26 (an isogenic strain of str

293 c(+) or LysM(+) cells were also sufficiently immunocompetent to raise a protective immune response to

294 breast cancer metastasis that develops in an immunocompetent tumor microenvironment has not been dete

295 ADCs had greater antitumor activity in immunocompetent versus immunodeficient mice, demonstrati

296 Fourteen patients (56%) were immunocompetent, while 44% had an underlying immunocompr

297 virus-associated secondary HLH by infecting immunocompetent wild-type mice with the beta-herpesvirus

298 CASE REPORT: A 30-year-old immunocompetent woman with complaints of an epigastric s

299 We randomized immunocompetent women with symptomatic HSV-2 infection t

300 rier more frequently and causes mortality in immunocompetent zebrafish.